Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for COVID-19

Next Previous
X
Search
Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for COVID-19

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remdesivir (Primary)
  • Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
  • Focus Registrational; Therapeutic Use
  • Acronyms REDPINE
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 09 Mar 2024 The trial has been completed in Portugal (End Date: 24 May 2022), according to European Clinical Trials Database record.
    • 14 Jul 2023 According to a Gilead Sciences media release, based on results from a Phase 1 Pharmacokinetic study (GS-US-540-9015), as well as results from the Phase 3 REDPINE trial, the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis.
    • 26 May 2023 According to a Gilead Sciences media release, based on results from a Phase 1 Pharmacokinetic study (GS-US-540-9015), as well as results from the Phase 3 REDPINE trial, he Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. The European Commission (EC) will review the CHMP recommendation.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top